A statement released earlier today by Mizuho Securities about Valeant Pharma (NYSE:VRX) bumps the target price to $25.00
- Updated: September 18, 2016
Indicating a possible upside of 0.00%, Mizuho Securities upped the estimated target of Valeant Pharma (NYSE:VRX) to $25.
On Wednesday August 10 2016, Piper Jaffray released a statement for Valeant Pharma(NYSE:VRX) upped the target price from $19.00 to $22.00. At the time, this indicated a possible downside of -0.22%.
Only yesterday Valeant Pharma (NYSE:VRX) traded 0.33% lower at $24.92. VRX’s 50-day moving average is $27.01 and its two hundred day moving average is $30.50. With the last stock price close down 10.55% relative to the 200-day average, compared to the Standard & Poor’s 500 Index which has fallen -0.01% over the same period. 10,477,284 shares of the stock exchanged hands, down from ann average volume of 27,140,400.
Recent Performance Graphic:
Valeant Pharma has a 52 week low of $18.55 and a 52 week high of $245.82. VRX’s market cap is currently $0.0.
A total of 18 analysts have reported on Valeant Pharma. Three firms rate the stock a strong buy, two firms rate the company a buy, 10 analyts rate the stock a hold, four firms rate the company to underperform, and finally one analystrate the stock as sell with a 12-month target stock price of $43.56
General Company Details For Valeant Pharma (NYSE:VRX)
Valeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices). It operates through two segments: Developed markets and Emerging markets. In the Developed Markets segment, it focuses on the areas of dermatology, neurology, gastrointestinal disorders, and eye health therapeutic classes. In the Emerging Markets segment, it focuses on primarily on branded generics, OTC products and medical devices. Its pharmaceutical products include Xifaxan, Solodyn and Glumetza. Its OTC products include PreserVision, CeraVe, Biotrue and Boston. Its other generic products include Latanoprost and Metronidazole. Its ophthalmic surgical products include intraocular lenses, such as Akreos, enVista, and Crystalens and Trulign.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.